vs

Side-by-side financial comparison of eXp World Holdings, Inc. (EXPI) and Steris (STE). Click either name above to swap in a different company.

Steris is the larger business by last-quarter revenue ($1.5B vs $1.2B, roughly 1.3× eXp World Holdings, Inc.). Steris runs the higher net margin — 12.9% vs -1.1%, a 14.0% gap on every dollar of revenue. On growth, Steris posted the faster year-over-year revenue change (9.2% vs 8.5%). Steris produced more free cash flow last quarter ($199.5M vs $11.9M). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs 12.4%).

eXp World Holdings, Inc. is a global cloud-based real estate services provider. It operates the eXp Realty brokerage network, leverages immersive virtual 3D campus environments to support agent collaboration and operations, serves residential and commercial real estate markets across over 20 countries, and offers complementary services including mortgage, title insurance and professional development resources for real estate practitioners.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

EXPI vs STE — Head-to-Head

Bigger by revenue
STE
STE
1.3× larger
STE
$1.5B
$1.2B
EXPI
Growing faster (revenue YoY)
STE
STE
+0.6% gap
STE
9.2%
8.5%
EXPI
Higher net margin
STE
STE
14.0% more per $
STE
12.9%
-1.1%
EXPI
More free cash flow
STE
STE
$187.6M more FCF
STE
$199.5M
$11.9M
EXPI
Faster 2-yr revenue CAGR
STE
STE
Annualised
STE
15.8%
12.4%
EXPI

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
EXPI
EXPI
STE
STE
Revenue
$1.2B
$1.5B
Net Profit
$-12.9M
$192.9M
Gross Margin
43.8%
Operating Margin
-1.1%
18.3%
Net Margin
-1.1%
12.9%
Revenue YoY
8.5%
9.2%
Net Profit YoY
-35.7%
11.2%
EPS (diluted)
$-0.08
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXPI
EXPI
STE
STE
Q4 25
$1.2B
$1.5B
Q3 25
$1.3B
$1.5B
Q2 25
$1.3B
$1.4B
Q1 25
$954.9M
$1.5B
Q4 24
$1.1B
$1.4B
Q3 24
$1.2B
$1.3B
Q2 24
$1.3B
$1.3B
Q1 24
$943.1M
$1.1B
Net Profit
EXPI
EXPI
STE
STE
Q4 25
$-12.9M
$192.9M
Q3 25
$3.5M
$191.9M
Q2 25
$-2.3M
$177.4M
Q1 25
$-11.0M
$145.7M
Q4 24
$-9.5M
$173.5M
Q3 24
$-8.5M
$150.0M
Q2 24
$12.4M
$145.4M
Q1 24
$-15.6M
$-1.4M
Gross Margin
EXPI
EXPI
STE
STE
Q4 25
43.8%
Q3 25
44.2%
Q2 25
45.1%
Q1 25
43.3%
Q4 24
44.5%
Q3 24
99.9%
43.6%
Q2 24
99.9%
44.7%
Q1 24
40.2%
Operating Margin
EXPI
EXPI
STE
STE
Q4 25
-1.1%
18.3%
Q3 25
0.3%
18.2%
Q2 25
-0.2%
17.7%
Q1 25
-1.1%
14.6%
Q4 24
-1.0%
17.9%
Q3 24
-0.7%
16.5%
Q2 24
1.4%
14.5%
Q1 24
-1.9%
22.0%
Net Margin
EXPI
EXPI
STE
STE
Q4 25
-1.1%
12.9%
Q3 25
0.3%
13.1%
Q2 25
-0.2%
12.8%
Q1 25
-1.2%
9.8%
Q4 24
-0.9%
12.7%
Q3 24
-0.7%
11.3%
Q2 24
1.0%
11.4%
Q1 24
-1.7%
-0.1%
EPS (diluted)
EXPI
EXPI
STE
STE
Q4 25
$-0.08
$1.96
Q3 25
$0.02
$1.94
Q2 25
$-0.01
$1.79
Q1 25
$-0.07
$1.48
Q4 24
$-0.06
$1.75
Q3 24
$-0.06
$1.51
Q2 24
$0.08
$1.46
Q1 24
$-0.10
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXPI
EXPI
STE
STE
Cash + ST InvestmentsLiquidity on hand
$124.2M
$423.7M
Total DebtLower is stronger
$1.9B
Stockholders' EquityBook value
$242.8M
$7.2B
Total Assets
$442.5M
$10.6B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXPI
EXPI
STE
STE
Q4 25
$124.2M
$423.7M
Q3 25
$112.8M
$319.2M
Q2 25
$94.6M
$279.7M
Q1 25
$115.7M
$171.7M
Q4 24
$113.6M
$155.2M
Q3 24
$130.4M
$172.2M
Q2 24
$108.4M
$198.3M
Q1 24
$109.2M
$207.0M
Total Debt
EXPI
EXPI
STE
STE
Q4 25
$1.9B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$2.0B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$3.1B
Stockholders' Equity
EXPI
EXPI
STE
STE
Q4 25
$242.8M
$7.2B
Q3 25
$235.3M
$7.0B
Q2 25
$218.4M
$7.0B
Q1 25
$212.0M
$6.6B
Q4 24
$204.9M
$6.4B
Q3 24
$211.1M
$6.6B
Q2 24
$220.3M
$6.4B
Q1 24
$222.4M
$6.3B
Total Assets
EXPI
EXPI
STE
STE
Q4 25
$442.5M
$10.6B
Q3 25
$458.7M
$10.4B
Q2 25
$481.2M
$10.4B
Q1 25
$435.8M
$10.1B
Q4 24
$390.7M
$10.0B
Q3 24
$432.6M
$10.2B
Q2 24
$457.4M
$10.1B
Q1 24
$426.7M
$11.1B
Debt / Equity
EXPI
EXPI
STE
STE
Q4 25
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
0.33×
Q2 24
0.35×
Q1 24
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXPI
EXPI
STE
STE
Operating Cash FlowLast quarter
$13.8M
$298.2M
Free Cash FlowOCF − Capex
$11.9M
$199.5M
FCF MarginFCF / Revenue
1.0%
13.3%
Capex IntensityCapex / Revenue
0.2%
6.6%
Cash ConversionOCF / Net Profit
1.55×
TTM Free Cash FlowTrailing 4 quarters
$109.0M
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXPI
EXPI
STE
STE
Q4 25
$13.8M
$298.2M
Q3 25
$28.9M
$287.8M
Q2 25
$36.1M
$420.0M
Q1 25
$39.8M
$260.8M
Q4 24
$13.7M
$332.8M
Q3 24
$46.0M
$250.7M
Q2 24
$71.1M
$303.7M
Q1 24
$60.7M
$254.8M
Free Cash Flow
EXPI
EXPI
STE
STE
Q4 25
$11.9M
$199.5M
Q3 25
$26.6M
$201.3M
Q2 25
$33.3M
$326.4M
Q1 25
$37.3M
$189.9M
Q4 24
$11.6M
$243.6M
Q3 24
$44.4M
$148.8M
Q2 24
$69.7M
$195.7M
Q1 24
$59.3M
$163.3M
FCF Margin
EXPI
EXPI
STE
STE
Q4 25
1.0%
13.3%
Q3 25
2.0%
13.8%
Q2 25
2.5%
23.5%
Q1 25
3.9%
12.8%
Q4 24
1.1%
17.8%
Q3 24
3.6%
11.2%
Q2 24
5.4%
15.3%
Q1 24
6.3%
14.6%
Capex Intensity
EXPI
EXPI
STE
STE
Q4 25
0.2%
6.6%
Q3 25
0.2%
5.9%
Q2 25
0.2%
6.7%
Q1 25
0.3%
4.8%
Q4 24
0.2%
6.5%
Q3 24
0.1%
7.7%
Q2 24
0.1%
8.4%
Q1 24
0.1%
8.2%
Cash Conversion
EXPI
EXPI
STE
STE
Q4 25
1.55×
Q3 25
8.26×
1.50×
Q2 25
2.37×
Q1 25
1.79×
Q4 24
1.92×
Q3 24
1.67×
Q2 24
5.75×
2.09×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXPI
EXPI

North American Realty$1.1B96%
International Realty$42.2M4%

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons